Combinational Effect of Intestinal and Hepatic CYP3A5 Genotypes on Tacrolimus Pharmacokinetics in Recipients of Living Donor Liver Transplantation
- 27 October 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 94 (8) , 866-872
Abstract
Background For living donor liver transplantation, the genetic association of CYP3A5 genotype of recipient’s native intestine and donor’s liver allograft with tacrolimus pharmacokinetics has not been explained completely considering liver regeneration time. The goal of the study was to investigate the longitudinal effects of recipient-donor combinational CYP3A5 genotypes on tacrolimus dose-normalized concentration (C/D ratio) in blood. Methods Tacrolimus blood concentrations were measured for 58 Korean adult living donor liver transplant recipients on tacrolimus-based immunosuppressants during 4 years of follow-up. CYP3A5 was genotyped for both recipient and donor, and the recipient-donor combinational genetic effect on tacrolimus C/D ratios were evaluated as a function of time after adjusting for covariates including demographics and clinical variables. Results CYP3A5 expresser recipients grafted from CYP3A5 expresser donors consistently had the least C/D ratio throughout the entire study period, whereas CYP3A5 expresser recipients grafted from CYP3A5 nonexpresser donors had an intermediate, and CYP3A5 nonexpresser recipients grafted from CYP3A5 nonexpresser donors had the largest C/D ratio (all P < 0.01). The CYP3A5 nonexpresser recipients grafted from CYP3A5 expresser donors showed a significant decrease from the largest to the intermediate in C/D ratio for the first month. Conclusions CYP3A5 genotypes of both recipient and donor were important factors influencing pharmacokinetic variability of tacrolimus. The recipient-donor combinational genetic effect on C/D ratio changed over time after transplantation.Keywords
This publication has 27 references indexed in Scilit:
- Effect of Liver Regeneration on the Pharmacokinetics of Immunosuppressive DrugsTransplantation Proceedings, 2009
- Liver Regeneration in Donors and Adult Recipients After Living Donor Liver TransplantationLiver Transplantation, 2008
- Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patientsPharmacogenetics and Genomics, 2008
- 4β-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and TanzaniansPharmacogenetics and Genomics, 2008
- Frequencies of CYP3A5 genotypes and haplotypes in a Korean populationJournal of Clinical Pharmacy and Therapeutics, 2008
- Improvement in Survival Associated With Adult-to-Adult Living Donor Liver TransplantationGastroenterology, 2007
- 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantationPharmacogenetics and Genomics, 2007
- Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patientsJournal of Clinical Pharmacy and Therapeutics, 2007
- CYP3A5 and CYP3A4 but not MDR1 Single-nucleotide Polymorphisms Determine Long-term Tacrolimus Disposition and Drug-related Nephrotoxicity in Renal RecipientsClinical Pharmacology & Therapeutics, 2007
- Early down-regulation of cytochrome P450 3A and 2E1 in the regenerating rat liver is not related to the loss of liver mass or the process of cellular proliferationLiver International, 2000